Compare AJANTA PHARMA with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DR. REDDYS LAB AJANTA PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 23.0 21.6 106.6% View Chart
P/BV x 4.1 3.2 125.5% View Chart
Dividend Yield % 0.9 0.7 118.8%  

Financials

 AJANTA PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
DR. REDDYS LAB
Mar-19
AJANTA PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,4222,875 49.5%   
Low Rs8981,888 47.5%   
Sales per share (Unadj.) Rs233.5930.2 25.1%  
Earnings per share (Unadj.) Rs44.0117.4 37.4%  
Cash flow per share (Unadj.) Rs52.2185.8 28.1%  
Dividends per share (Unadj.) Rs9.0020.00 45.0%  
Dividend yield (eoy) %0.80.8 92.4%  
Book value per share (Unadj.) Rs255.1844.4 30.2%  
Shares outstanding (eoy) m88.02166.07 53.0%   
Bonus/Rights/Conversions BBESOP-  
Price / Sales ratio x5.02.6 194.0%   
Avg P/E ratio x26.420.3 130.1%  
P/CF ratio (eoy) x22.212.8 173.4%  
Price / Book Value ratio x4.52.8 161.2%  
Dividend payout %20.517.0 120.2%   
Avg Mkt Cap Rs m102,081395,496 25.8%   
No. of employees `0006.822.0 31.0%   
Total wages/salary Rs m4,30733,562 12.8%   
Avg. sales/employee Rs Th3,022.67,032.8 43.0%   
Avg. wages/employee Rs Th633.41,527.9 41.5%   
Avg. net profit/employee Rs Th569.1887.7 64.1%   
INCOME DATA
Net Sales Rs m20,554154,482 13.3%  
Other income Rs m2113,375 6.2%   
Total revenues Rs m20,765157,857 13.2%   
Gross profit Rs m5,66431,782 17.8%  
Depreciation Rs m72111,348 6.4%   
Interest Rs m12889 1.3%   
Profit before tax Rs m5,14322,920 22.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2733,858 33.0%   
Profit after tax Rs m3,87019,500 19.8%  
Gross profit margin %27.620.6 134.0%  
Effective tax rate %24.816.8 147.1%   
Net profit margin %18.812.6 149.2%  
BALANCE SHEET DATA
Current assets Rs m11,812111,101 10.6%   
Current liabilities Rs m3,77658,973 6.4%   
Net working cap to sales %39.133.7 115.9%  
Current ratio x3.11.9 166.0%  
Inventory Days Days7779 97.5%  
Debtors Days Days8294 86.6%  
Net fixed assets Rs m14,398101,245 14.2%   
Share capital Rs m175830 21.1%   
"Free" reserves Rs m22,277139,406 16.0%   
Net worth Rs m22,452140,236 16.0%   
Long term debt Rs m722,000 0.0%   
Total assets Rs m26,962224,656 12.0%  
Interest coverage x444.326.8 1,659.1%   
Debt to equity ratio x00.2 0.2%  
Sales to assets ratio x0.80.7 110.9%   
Return on assets %14.49.1 158.6%  
Return on equity %17.213.9 123.9%  
Return on capital %23.014.9 153.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,68288,673 12.0%   
Fx outflow Rs m2,10219,104 11.0%   
Net fx Rs m8,58069,569 12.3%   
CASH FLOW
From Operations Rs m3,74828,704 13.1%  
From Investments Rs m-2,228-7,727 28.8%  
From Financial Activity Rs m-1,475-21,326 6.9%  
Net Cashflow Rs m45-314 -14.4%  

Share Holding

Indian Promoters % 73.8 25.5 289.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 5.4 28.7%  
FIIs % 7.6 35.3 21.5%  
ADR/GDR % 0.0 18.5 -  
Free float % 17.0 15.3 111.1%  
Shareholders   20,968 75,885 27.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  ALEMBIC PHARMA  ELDER PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Rally; Sensex Zooms 1,250 Points(12:30 pm)

Share markets in India are presently trading on a strong note, cheering the government's move to cut corporate tax rates to boost economic growth.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 54.6% (Quarterly Result Update)

Feb 1, 2019 | Updated on Feb 1, 2019

For the quarter ended December 2018, AJANTA PHARMA has posted a net profit of Rs 669 m (down 54.6% YoY). Sales on the other hand came in at Rs 5 bn (down 17.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

My 7 Stocks to Buy Are Companies Which Will Be a Big Part of New India(The 5 Minute Wrapup)

Sep 19, 2019

The India we knew is changing. Here's how you can benefit from this change.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

Did the Tax Bonanza Really Deserve a 2,000-point Gain on the Sensex?(Profit Hunter)

Sep 20, 2019

Are investors overdoing their euphoria post the corporate tax cut bonanza?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Sep 23, 2019 12:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS